

XXIII Assemblea MaNGO 2026

Bridging the gap: translating clinical trials into every day gynecologic oncology

11-13 June, 2026

Brescia - Centro Paolo VI

Responsabile Scientifico:

Eliana Bignotti, Franco Edoardo Odicino, Giulia Tasca, Germana Tognon, Valentina Zizioli

Evento RES con accreditamento ECM nazionale - Partecipanti Previsti: 150

Figure accreditate: Biologi e Medici specialisti in Oncologia, Ginecologia e Ostetricia, Chirurgia Generale, Anatomia Patologica, Radioterapia, Radiodiagnostica, Medici di famiglia, Infermieri

RAZIONALE:

I progressi della ricerca clinica in oncologia ginecologica hanno profondamente modificato gli approcci diagnostico-terapeutici, introducendo la classificazione molecolare, strategie di trattamento sempre più personalizzate e nuovi modelli di studio cooperativo. Tuttavia, la traduzione dei risultati dei trial clinici nella pratica clinica quotidiana rimane una sfida complessa, condizionata da aspetti organizzativi, sostenibilità del sistema sanitario e accesso equo alle cure. La XXIII Assemblea MaNGO 2026 si propone come momento di confronto multidisciplinare per colmare il divario tra evidenze scientifiche e real life, favorendo un dialogo strutturato tra clinici, ricercatori e rappresentanti delle associazioni di pazienti.

Attraverso sessioni dedicate ai principali tumori ginecologici, ai tumori rari e agli studi MaNGO-ENGOT in corso e in fase di avvio, l'evento mira a condividere aggiornamenti scientifici, discutere nuove proposte di ricerca e promuovere l'implementazione di percorsi di cura innovativi, sostenibili e centrati sulla paziente, rafforzando il ruolo della ricerca collaborativa nella pratica clinica quotidiana.

PROGRAMMA PRELIMINARE:

June 11th, 2026

15:15-15:45 Registration and welcome coffee

15:45-16:00 Welcome and Introduction (F. E. Odicino, G. Tognon)

16:00-16:45 Access to cancer treatment: financial difficulties and system sustainability : Round table with representatives of patients and for patients associations

Chairs: A. Ferrero, M.C. Petrella

(Reference : Patient-Reported financial toxicity within the italian public healthcare system, [F.De Vita et al, Annals of Research in Oncology Vol. 2\(2\), 94-104, 2022](#)).

16:45-17:15 A modern perspective on women's cancer prevention (S. Pecorelli)

17:15-18:15 : NO ECM Sponsored Symposium - GSK

18:15 Closing of works

June 12th, 2026

08:45- 09:00 Welcome

Session 1: Endometrial cancer: the new therapeutic algorithm

Chairs: D. Katsaros, A. A. Lissoni, G. Tognon

09:00 – 09:25 Surgical tailoring based on new molecular profiling (F.E. Odicino)

09:25 – 09:50 The New endometrial cancer guidelines ESGO/ESTRO/ESP 2025 with a focus on hormonal Therapy (J.M.A. Pijnenborg)

09:50-10:00 Discussion

10:00-10:20 Coffee break

Session 2: Endometrial cancer studies

Chairs: E. Biagioli, G. Tasca, F. Tomao

10:20-10:30 Short summary on ongoing MaNGO-ENGOT studies (E.Biagioli)

10:30-10:45 Opening studies in Endometrial Cancer first line (MaNGO-ENGOT) (G. Tasca)

10:45-11:00 Opening studies in Endometrial Cancer at relapse (MaNGO-ENGOT) (F.Tomao)

11:00-12:00 New ideas/proposals and discussion

Session 3: Cervical cancer

Chairs: A. Ardizzoia, A. Bologna , F. Raspagliesi

12:00- 12:25: Sentinel-Lymph node biopsy vs systematic lymphadenectomy in the management of cervical cancer (P. Zola)

12:25- 12:50 : Therapeutic management of cervical cancer recurrence: an evolving clinical landscape (N. Colombo)

12:50-13:00 Discussion

13:00-14:00 Lunch

Session 4: Cervical cancer studies

Chairs: E. Piovano, V. Zizioli

14:00-14:10 Short summary on ongoing MaNGO-ENGOT studies (E.Piovano)

14:10-14:20 Opening studies in cervical cancer (MaNGO-ENGOT) (V.Zizioli)

14:20-15:10 New ideas/proposals and discussion

Session 5 Rare tumors and miscellaneous

Chairs: M. D’Incalci, A. Gadducci, G. Tognon

15:10-15:35 ESCAT in routine care: feasibility of molecularly-guided treatment in gynecologic tumors (I. Colombo)

15:35-16:00 Integrated mutational landscape analysis of uterine serous carcinoma (USC), a rare but highly aggressive variant of endometrial cancer: Un update (A.D. Santin)

16:00-16:10 Discussion

16:10-16:30 Coffee break

Session 6 Rare tumors and miscellaneous studies

Chairs: L. Ceppi, M.C. Petrella

16:30-16:40 Short summary on ongoing MaNGO-ENGOT studies (M.C. Petrella)

16:40-16:50 Opening studies in rare tumors (MaNGO-ENGOT) (L.Ceppi)

16:50-17:30 New ideas/proposals and discussion

17:30-18:30: ECM Sponsored Symposium – ASTRAZENECA + MSD

18:30 Closing of works

June 13th, 2026

Session 7 : Ovarian Cancer

Chairs: N. Colombo, M. D’Incalci, R. Fossati

08:30 -8:55 Are all HRD positive Ovarian Cancer platinum and PARP sensitive? And why do some HRD negative Ovarian Cancer respond so well? (I. McNeish)

08:55- 09:20 Decoding BRCA1 and BRCA2 mutations in high-grade serous ovarian cancer (BRIGHT Study): impact of location and type of mutation on prognosis and PARPi response (E. Bignotti)

09:20-09:30 Discussion

Session 8 : Ovarian Cancer studies

Chairs: G. Tasca, M. Mantiero, V. Zizioli

09:30-09:40 Short summary on ongoing MaNGO-ENGOT studies (V. Zizioli)

09:40-09:50 Opening studies in ovarian cancer first line (MaNGO-ENGOT) (G. Tasca)

09:50-10:00 Opening studies in ovarian cancer at relapse (MaNGO-ENGOT) (M. Mantiero)

10:00- 10:50 New ideas/proposals (max 2-3 proposals) and discussion

10:50-11:10 Coffee Break

11:10-11:30 News from 7th [GCIG Ovarian Cancer Consensus Conference](#) (2026-Toronto) (A.M.Ferrero, D. Katsaros, F. Multinu)

11:30-12:20 NO ECM Sponsored Symposium – ABBVIE

12:20-13:00 NO ECM Sponsored Symposium

13:00-13:30 NO ECM Sponsored Symposium

13: 30 Final remarks and conclusions

Chairs: M. D’Incalci, F. Odcino, G. Tognon

13: 40 Light Lunch